Immune booster: donor NK cells aim to stop leukemia return after transplant

NCT ID NCT07256210

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This clinical trial tests whether infusions of donor natural killer (NK) cells, given before and after a stem cell transplant, can safely prevent leukemia from coming back in children and young adults with hard-to-treat acute leukemia. The study enrolls 15 patients aged 0 to 25 with chemorefractory or minimal residual disease positive leukemia. Researchers will monitor side effects and the maximum tolerated dose, as well as how well the treatment clears leukemia from the bone marrow.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Donor-derived natural killer (NK) cells

What this could lead to

If successful, this approach could reduce the risk of leukemia returning after a stem cell transplant, offering a better chance of long-term remission for patients with difficult-to-treat acute leukemia.

What could go wrong

This is a small, early-phase trial with only 15 participants, so results may not apply broadly. There is a risk of serious side effects like graft-versus-host disease or infusion reactions, and the treatment may not prevent relapse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute biphenotypic leukemia acute myeloid leukemia leukemia mixed phenotype acute leukemia Precursor T-Cell Lymphoblastic Leukemia-Lymphoma T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dmitry Rogachev Federal Research and Clinical Centre of Paediatric Haematology, Oncology and Immunology

    RECRUITING

    Moscow, 117997, Russia

    Contact Phone: •••-•••-•••• Email: •••••@•••••